Ipratropium + Fenoterol Farmak (Fenoterol Hydrobromide, Ipratropium Bromide Anhydrous)

Fenoterol is a selective β2‑adrenergic agonist. When inhaled, it binds to β2 receptors on airway smooth muscle, stimulating adenylate cyclase, raising cyclic AMP levels, and causing muscle relaxation. This results in widened airways and improved airflow, especially during an asthma or COPD exacerbation.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s severity of disease, age, and response to therapy. Healthcare professionals tailor the inhalation regimen to achieve optimal bronchodilation while minimizing side effects.

Safety data for this combination in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with other fixed‑dose inhalers such as salbutamol‑ipratropium, fenoterol‑ipratropium offers a slightly longer β2‑agonist action and may provide enhanced bronchodilation in some patients. Choice of therapy depends on individual response, physician preference, and local formulary guidelines.

Store the inhaler at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the cap is securely closed when not in use to maintain dose integrity.

The medication is delivered via a metered‑dose inhaler (MDI) or nebulizer, as directed by the prescriber. Patients should inhale the prescribed number of puffs or nebulized doses, exhale fully before inhalation, and hold their breath for a few seconds to allow optimal drug deposition in the lungs.

Serious adverse events include paradoxical bronchospasm, severe cardiac arrhythmias, and anaphylactic reactions. Patients should seek immediate medical attention if they experience sudden worsening of breathing, chest pain, palpitations, or signs of an allergic reaction such as swelling of the face or throat.

Individuals with a known hypersensitivity to fenoterol, ipratropium, or any excipients in the formulation should avoid this product. It is also contraindicated in patients with acute narrow‑angle glaucoma or urinary retention due to prostate enlargement, unless specifically advised by a physician.